3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
25
Leukemia
13
Neuroblastoma
12
Myelodysplastic Syndromes
12
Multiple Myeloma
12
Recurrence
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma
8
Sarcoma
7
Medulloblastoma
7
Astrocytoma
7
Lymphoma, Non-Hodgkin
6
Wilms Tumor
5
Osteosarcoma
5
Central Nervous System Neoplasms
5
Brain Neoplasms
5
Sarcoma, Ewing
4
Rhabdoid Tumor
4
Retinoblastoma
4
Optic Nerve Glioma
4
Neoplasms
4
Myeloproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia, Biphenotypic, Acute
4
Hodgkin Disease
4
Hematologic Neoplasms
4
Burkitt Lymphoma
4
Testicular Neoplasms
3
Interventions
Cisplatin
21
Etoposide
20
Carboplatin
20
Topotecan
13
pembrolizumab
12
durvalumab
11
Paclitaxel
10
Irinotecan
9
Nivolumab
7
Gemcitabine
7
tremelimumab
6
atezolizumab
6
Radiotherapy
6
Docetaxel
6
Pemetrexed
5
Ipilimumab
5
Cyclophosphamide
5
rovalpituzumab tesirine
4
budigalimab
4
Specimen Handling
4
Injections
4
Doxorubicin
4
Bortezomib
4
130-nm albumin-bound paclitaxel
4
venetoclax
3
talazoparib
3
olaparib
3
fludarabine
3
etoposide phosphate
3
Platinum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Small Cell Lung Carcinoma
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01840579
2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1
Completed
57 enrolled
60 charts